U
VNDA icon

UBS’s Vanda Pharmaceuticals VNDA Stock Holding History

UBS’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$779K Buy
+75,000
New +$983K ﹤0.01% 3829
2014
Q1 		– Sell
-4,000
Closed -$50K – 10849
2013
Q4 		$50K Sell
4,000
-7,500
-65% -$75.3K ﹤0.01% 6963
2013
Q3 		$126K Buy
+11,500
New +$123K ﹤0.01% 5752

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SCA
Signpost Capital Advisors New York $34.2M AUM 5.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's VNDA Position: Q3 2014 in Review

UBS increased its Vanda Pharmaceuticals (VNDA) stake by 553% in Q3 2014, buying an estimated $145K and bringing the position to 13,059 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #5604.

UBS first reported a position in VNDA in Q4 2013 and has held it in 4 quarters since. 101 funds tracked by Wall St. Rank hold VNDA as of Q3 2014.

  • UBS held 13,059 shares of Vanda Pharmaceuticals worth $136K as of Q3 2014.
  • UBS bought 11,059 Vanda Pharmaceuticals shares in Q3 2014, an estimated $145K.
  • Vanda Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5604 holding.
  • UBS first reported a position in Vanda Pharmaceuticals in Q4 2013 and has held it in 4 quarters since.
  • 101 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.